<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14862">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789008</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC/12-01</org_study_id>
    <secondary_id>2012-A01171-42</secondary_id>
    <nct_id>NCT01789008</nct_id>
  </id_info>
  <brief_title>Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease.</brief_title>
  <acronym>FIBR-OH</acronym>
  <official_title>Interest of Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Didease in Alcoholic Patients in Weaning.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcoholic liver disease is the most frequent complication of excessive alcohol consumption.
      Early diagnosis of alcoholic liver disease is essential to avoid its complications that
      could be fatal. To date, the reference diagnostic tool is an invasive procedure: the liver
      biopsy. The transient elastography is a useful tool for early diagnosis of liver fibrosis.
      This tool is validated in the diagnosis of liver fibrosis due to C chronic hepatitis.
      Because it is non-invasive, fast, given immediate results; transient elastography could be
      repeated in alcoholic patients for liver fibrosis follow-up. In the present study, the
      investigators propose to realize liver biopsy and transient elastography in 300 alcoholic
      patients in weaning to evaluate the transient elastography accuracy in the exclusion of
      sever liver fibrosis (Metavir 3 and 4). The reference liver fibrosis diagnosis tool will be
      the liver biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Accuracy of transient elastography will be evaluated by AUC</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Alcoholism</condition>
  <condition>Liver Disease</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Transient elastography</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liver biopsie</intervention_name>
    <arm_group_label>Transient elastography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients more than 18 years old; hospitalised for alcoholic weaning; with an
             alcoholic liver disease; with at risk alcoholic consumption; with an indication of
             liver biopsy; with a signed consentment.

        Exclusion Criteria:

          -  patients with a cirrhosis; with other causes of liver disease; with a
             contraindication of liver biopsy; having had a liver biopsy in the last 3 years;
             pregnancy; major benefiting from a legal protective measure; no coverage care.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Romain Moirand, MD, PhD</last_name>
    <phone>02 99 28 42 97</phone>
    <email>romain.moirand@univ-rennes1.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rennes university hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Moirand, MD, PhD</last_name>
      <phone>02 99 28 42 97</phone>
      <email>romain.moirand@univ-rennes1.fr</email>
    </contact>
    <investigator>
      <last_name>Romain Moirand, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>February 8, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transient elastography</keyword>
  <keyword>Alcoholic liver disease</keyword>
  <keyword>liver fibrosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
